Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) Operating Expenses (2016 - 2025)

Historic Operating Expenses for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to $2.3 million.

  • International Stem Cell's Operating Expenses rose 26.44% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 245.84%. This contributed to the annual value of $9.2 million for FY2024, which is 829.39% up from last year.
  • According to the latest figures from Q3 2025, International Stem Cell's Operating Expenses is $2.3 million, which was up 26.44% from $2.3 million recorded in Q2 2025.
  • In the past 5 years, International Stem Cell's Operating Expenses ranged from a high of $2.5 million in Q3 2021 and a low of $2.0 million during Q2 2023
  • For the 5-year period, International Stem Cell's Operating Expenses averaged around $2.2 million, with its median value being $2.2 million (2021).
  • In the last 5 years, International Stem Cell's Operating Expenses tumbled by 2095.91% in 2021 and then soared by 1070.06% in 2024.
  • International Stem Cell's Operating Expenses (Quarter) stood at $2.2 million in 2021, then increased by 9.37% to $2.4 million in 2022, then decreased by 2.36% to $2.3 million in 2023, then grew by 3.55% to $2.4 million in 2024, then decreased by 5.01% to $2.3 million in 2025.
  • Its Operating Expenses was $2.3 million in Q3 2025, compared to $2.3 million in Q2 2025 and $2.3 million in Q1 2025.